PT - JOURNAL ARTICLE AU - Peter T.A. Linders AU - Eveline C.F. Gerretsen AU - Angel Ashikov AU - Mari-Anne Vals AU - Natalia H. Revelo AU - Richard Arts AU - Melissa Baerenfaenger AU - Fokje Zijlstra AU - Karin Huijben AU - Kimiyo Raymond AU - Kai Muru AU - Olga Fjodorova AU - Sander Pajusalu AU - Katrin Õunap AU - Martin ter Beest AU - Dirk Lefeber AU - Geert van den Bogaart TI - Congenital disorder of glycosylation caused by starting site-specific variant in syntaxin-5 AID - 10.1101/2020.03.30.20044438 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.30.20044438 4099 - http://medrxiv.org/content/early/2020/03/31/2020.03.30.20044438.short 4100 - http://medrxiv.org/content/early/2020/03/31/2020.03.30.20044438.full AB - The SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein syntaxin-5 (Stx5) is essential for Golgi transport. In humans, the STX5 mRNA encodes two protein isoforms, Stx5 Long (Stx5L) from the first starting methionine and Stx5 Short (Stx5S) from an alternative starting methionine at position 55. In this study, we identified a novel human disorder caused by a single missense substitution in the second starting methionine (p.M55V), resulting in complete loss of the short isoform. Patients suffer from an early fatal multisystem disease, including severe liver disease, skeletal abnormalities and abnormal glycosylation. Whereas Golgi morphology was unaltered, primary human dermal fibroblasts isolated from these patients showed defective glycosylation and mislocalization of glycosyltransferases. Measurements of anterograde trafficking, based on biotin-synchronizable forms of Stx5 (the RUSH system), and of cognate binding SNAREs, based on Förster resonance energy transfer (FRET), revealed that the short isoform of Stx5 is essential for intra-Golgi transport. This is the first time a mutation in an alternative starting codon is linked to human disease, demonstrating that the site of translation initiation is an important new layer of regulating protein trafficking.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN.H.R. is funded by a Long-Term Fellowship from the European Molecular Biology Organization (EMBO-LTF, ALTF 232-2016) and a Veni grant from the Netherlands Organization for Scientific Research (016.VENI.171.097). G.v.d.B. is funded by a Young Investigator Grant from the Human Frontier Science Program (HFSP; RGY0080/2018) and a Vidi grant from the Netherlands Organisation for Scientific Research (NWO-ALW VIDI 864.14.001). D.J.L. is funded by a Vidi grant (ZONMW VIDI 917.13.359), a ZONMW Medium Investment Grant (40-00506-98-9001) from the Netherlands Organisation for Scientific Research, and Erare grants EUROCDG2 and Euroglycanomics. K.Õ, M-A.V., S.P., and K.M. were supported by the Estonian Research Council grants GARLA8175, PUT355, PUTJD827 and PRG471.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMicroarray data, exome sequencing data and ImageJ macros for quantification of the RUSH experiments are available upon request.